Ivabradine – is it “beautiful” drug for patients with coronary artery disease and left ventricular dysfunction? BEAUTIFUL study Review article
Article Sidebar
Published:
Mar 31, 2009
Keywords:
ivabradine, coronary artery disease, left ventricular dysfunction
Main Article Content
Abstract
BEAUTIFUL study was designed to test whether an addition of ivabradine to the standard therapy reduces cardiovascular mortality and morbidity in patients with stable angina and leftventricular dysfunction. In patients with baseline heart rate of 70 beats per minute or greater ivabradine reduced admission to hospital due to myocardial infarction, unstable angina, and coronary revascularization.
Article Details
How to Cite
Trzeciak, P. (2009). Ivabradine – is it “beautiful” drug for patients with coronary artery disease and left ventricular dysfunction? BEAUTIFUL study. Medycyna Faktow (J EBM), 2(1(2), 17-23. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2677
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Kannel W.B., Kannel C., Paffenbarger R.E. Jr., Cupples L.A.: Heart rate and cardiovascular mortality: the Framingham Study. Am. Heart J. 1987; 113: 1489-1494.
2. Palatini P., Julius S.: Elevated heart rate: a major risk factor for cardiovascular disease. Clin. Exp. Hypertens. 2004; 26: 637-644.
3. Diaz A., Bourassa M.G., Guertin M.C., Tardiff J.C.: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 2005; 26: 967-974.
4. Kolloch R., Legler U.F., Champion A. et al.: impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trondalapril Study (INVEST). Eur. Heart J. 2008; 29: 1327-1334.
5. Kasprzak J.D., Tymiński M.: Iwabradyna w badaniu Beautiful – implikacje dla klinicysty. Kardiologia po Dyplomie 2008, wrzesień; wydanie specjalne: 3-7.
6. Przybysz B., Serafin A., Filipiak K.J.: Iwabradyna – alternatywa czy „wartość dodana” w stosunku do leków β-adrenolitycznych? Choroby Serca i Naczyń 2007; 4: 169-176.
7. Joannides R., Moore N., Iacob M.: Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br. J. Clin. Pharmacol. 2006; 61: 127-137.
8. Manz M., Reuter M., Lauck G., Omran H., Jung W.: A single intravenous dose of ivabradine, a novel I (f ) inhibitor, lowers heart rate but dose not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-155.
9. Camm A.J., Lau C.P.: Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R. D. 2003; 4: 83-89.
10. Fox K., Garcia M.A., Ardissino D., Buszmen P., Camici P.G., Crea F., Daly C., De Backer G., Hjemdahl P., Lopes-Sendon J., Marco J., Morais J., Pepper J., Sechtem U., Simoons M., Thygesen K.: Task force on the management of stable angina pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG): Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27: 1341-1381.
11. Graham I., Atar D., Borch-Johnsen K.: European guidlines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007; 28: 2375-2414.
12. Fox K., Ferrari R., Tendera M., Steg P.G., Ford I.: Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I (f ) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am. Heart J. 2006; 152: 860-866.
13. The BEAUTIFUL Study Group: The BEAUTIFUL Study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline characteristics of the study population. Cardiology 2008; 110: 271-282.
14. MorBidity-mortality EvAlUaTion of the I (f ) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction: Breaking new ground in coronary artery disease. 2008 Servier, edited by Fox K, Ferrari R on behalf of the BEAUTIFUL Executive Committee.
15. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. (on behalf of the Beautiful Investigators): Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial [online: www.thelancet.com, published August 31, 2008].
2. Palatini P., Julius S.: Elevated heart rate: a major risk factor for cardiovascular disease. Clin. Exp. Hypertens. 2004; 26: 637-644.
3. Diaz A., Bourassa M.G., Guertin M.C., Tardiff J.C.: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 2005; 26: 967-974.
4. Kolloch R., Legler U.F., Champion A. et al.: impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trondalapril Study (INVEST). Eur. Heart J. 2008; 29: 1327-1334.
5. Kasprzak J.D., Tymiński M.: Iwabradyna w badaniu Beautiful – implikacje dla klinicysty. Kardiologia po Dyplomie 2008, wrzesień; wydanie specjalne: 3-7.
6. Przybysz B., Serafin A., Filipiak K.J.: Iwabradyna – alternatywa czy „wartość dodana” w stosunku do leków β-adrenolitycznych? Choroby Serca i Naczyń 2007; 4: 169-176.
7. Joannides R., Moore N., Iacob M.: Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br. J. Clin. Pharmacol. 2006; 61: 127-137.
8. Manz M., Reuter M., Lauck G., Omran H., Jung W.: A single intravenous dose of ivabradine, a novel I (f ) inhibitor, lowers heart rate but dose not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003; 100: 149-155.
9. Camm A.J., Lau C.P.: Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R. D. 2003; 4: 83-89.
10. Fox K., Garcia M.A., Ardissino D., Buszmen P., Camici P.G., Crea F., Daly C., De Backer G., Hjemdahl P., Lopes-Sendon J., Marco J., Morais J., Pepper J., Sechtem U., Simoons M., Thygesen K.: Task force on the management of stable angina pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG): Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27: 1341-1381.
11. Graham I., Atar D., Borch-Johnsen K.: European guidlines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007; 28: 2375-2414.
12. Fox K., Ferrari R., Tendera M., Steg P.G., Ford I.: Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I (f ) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am. Heart J. 2006; 152: 860-866.
13. The BEAUTIFUL Study Group: The BEAUTIFUL Study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline characteristics of the study population. Cardiology 2008; 110: 271-282.
14. MorBidity-mortality EvAlUaTion of the I (f ) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction: Breaking new ground in coronary artery disease. 2008 Servier, edited by Fox K, Ferrari R on behalf of the BEAUTIFUL Executive Committee.
15. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. (on behalf of the Beautiful Investigators): Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial [online: www.thelancet.com, published August 31, 2008].